Los Angeles Capital Management LLC Trims Stock Holdings in Stryker Co. (NYSE:SYK)

Los Angeles Capital Management LLC reduced its stake in Stryker Co. (NYSE:SYK) by 25.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 316,363 shares of the medical technology company’s stock after selling 108,894 shares during the period. Los Angeles Capital Management LLC owned approximately 0.08% of Stryker worth $94,738,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Farmers & Merchants Trust Co of Chambersburg PA raised its holdings in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after buying an additional 61 shares during the period. Rogco LP acquired a new position in Stryker in the 4th quarter valued at about $30,000. HBC Financial Services PLLC acquired a new position in Stryker in the 4th quarter valued at about $37,000. Bourgeon Capital Management LLC acquired a new position in Stryker in the 4th quarter valued at about $37,000. Finally, Venturi Wealth Management LLC grew its position in Stryker by 97.1% in the 4th quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock valued at $41,000 after acquiring an additional 67 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The disclosure for this sale can be found here. Over the last quarter, insiders sold 212,109 shares of company stock worth $72,845,768. 5.90% of the stock is owned by insiders.

Stryker Stock Down 0.3 %

SYK stock traded down $0.91 during trading on Thursday, hitting $327.21. 1,033,797 shares of the company’s stock were exchanged, compared to its average volume of 1,315,318. The business has a 50-day moving average price of $348.05 and a two-hundred day moving average price of $316.78. The stock has a market capitalization of $124.49 billion, a price-to-earnings ratio of 37.46, a PEG ratio of 2.71 and a beta of 0.91. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. Stryker had a return on equity of 23.44% and a net margin of 16.03%. The company had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. During the same quarter in the previous year, the business earned $2.14 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, equities research analysts expect that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date was Wednesday, March 27th. Stryker’s dividend payout ratio is currently 36.53%.

Analyst Upgrades and Downgrades

SYK has been the subject of several research reports. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a research report on Wednesday, January 31st. Royal Bank of Canada lifted their target price on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and lifted their target price for the company from $315.00 to $360.00 in a research report on Wednesday, January 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research report on Wednesday. Finally, TD Cowen boosted their price objective on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $357.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.